In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including:

  • The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab
  • Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone
  • Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy
  • How to set up and maintain a REMS program

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Syeda Saba Kareem, PharmD, BCOP
Clinical Pharmacy Supervisor
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Sara A. Scott, PharmD, BCOP
Clinical Pharmacy Specialist, 
Multiple Myeloma
Emory Winship Cancer Institute
Atlanta, Georgia

Link to full program: 
https://bit.ly/3RUyrMx


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Decera Clinical Education. Innehållet i podden är skapat av Decera Clinical Education och inte av, eller tillsammans med, Poddtoppen.